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Objectives: To evaluate initial treatment and risk factors for amputation-free survival in patients with
critical limb ischaemia (CLI).
Design: Prospective clinical cohort study at a single vascular surgical centre in Germany.
Methods: Data on 104 consecutive patients (115 ischaemic limbs) presenting with their ﬁrst episode of
CLI were collected prospectively over a 3-year period. Initial treatment was classiﬁed as conservative
therapy, intervention, surgery, or major amputation. Patient co-morbidities were assessed by uni- and
multivariate analysis to determine risk factors for limb salvage, survival and amputation-free survival.
Results: Indications for treatment were rest pain in 27 (23.5%) and tissue loss in 88 (76.5%) limbs.
Revascularisation was attempted in 65% of all limbs: 45% by intervention and 55% by surgery. In 9%
primary amputation was necessary and 22% received conservative therapy. Median follow-up was 28
months (1e42). The 3-year limb salvage, patient survival, and amputation-free survival rates were 73%,
41%, and 31%, respectively. Diabetes, cardiac disease and renal insufﬁciency were associated with poor
survival. Combined cardiac and renal disease adversely affected amputation-free survival (HR, 3.68; 95%
CI, 1.51e8.94; P < 0.001).
Conclusions: At least two third of all patients presenting with CLI can be offered some type of direct
revascularisation. In patients with major cardiac disease and renal insufﬁciency, a poor outcome in terms
of amputation-free survival is to be anticipated.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The incidence of chronic critical limb ischaemia (CLI) is esti-
mated to be 50e100 per 100,000 every year in developed coun-
tries.1 With the ageing population, the increasing prevalence of
diabetes even among young people2 and the persisting high
consumption of tobacco, the number of patients with limb-
threatening ischaemia will continue to increase in the foreseeable
future. It can be expected that many of these patients will require
treatment for limb salvage.
Modern vascular medicine offers a wide variety of conservative,
endovascular and operative therapies for patients with CLI.
Advances in peripheral bypass surgery resulted in acceptable
outcome even after technically demanding arterial reconstructions
such as distal-origin bypass originating from arteries below the
knee or pedal bypass with 5-year limb salvage rates of 78% in some
series,3,4 justifying an aggressive approach towards infrainguinal
bypass grafting for limb salvage. Furthermore, endovascularx: þ49 731 1710 1978.
ardt).
ciety for Vascular Surgery. Publishetreatment with balloon angioplasty proved to be a valuable alter-
native in selected patients with severe ischaemia.5 However,
although this problematic group of patients is of increasing
importance for the public health system, there are no consistent
data yet on patients with limb-threatening ischaemia in terms of
initial treatment and overall outcome in Germany.
The primary objective of this prospective study was to evaluate
the initial treatment and to determine the amputation-free survival
rate in patients presenting with their ﬁrst episode of CLI. Further-
more, we tried to identify preoperative patient demographics and
co-morbid diseases associated with adverse effects on survival and
amputation-free survival.
Materials and Methods
Between October 2004 and June 2005, pertinent demographic
and clinical data from 104 consecutive patients (115 ischaemic
limbs) referring to the Department of Vascular Surgery, Klinikum
Augsburg, Germany, for their ﬁrst episode of CLI, were prospec-
tively recorded. CLI was deﬁned as ischaemic rest pain for mored by Elsevier Ltd. All rights reserved.
Table 1
Patient (n ¼ 104) demographics, mode of presentation, risk factors,
and co-morbidities.
Demographic
Age [years (IQR)] 77 (69e82)
Male 57 (54.8%)
Mode of presentation
Rest pain 23 (22.1%)
Tissue loss 81 (77.9%)
Risk factors
Diabetes 57 (54.8%)
Hypertension 87 (83.7%)
Hyperlipidemia 21 (20.2%)
Smoking
Current 20 (19.2%)
Former 25 (24.0%)
Comorbid diseases
Cardiac disease 72 (69.2%)
MI
CHF
Renal disease
Renal insufﬁciency 46 (44.2%)
ESRD 9 (8.7%)
Cerebrovascular disease
TIA 2 (1.9%)
Stroke 19 (18.5%)
Pulmonary disease 16 (15.4%)
MI, myocardial infarction; CHF, congestive heart failure; ESRD, end-
stage renal disease; TIA, transient ischaemic attack.
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consistent with Fontaine stages IV and Rutherford classes 5 or 6. All
datawere entered into a database at the time of ﬁrst admission, and
the registry was updated periodically with patient follow-up data
up to 36 months.
Primary outcome measures considered were initial treatment
during the ﬁrst admission for CLI and 3-year patient survival rate
and amputation-free survival rate. Initial treatment was classi-
ﬁed as: conservative treatment (medical therapy with prosta-
noids, and/or minor surgical treatment including topical wound
therapy, lumbar sympathicolysis, minor amputation of toe, ray or
transmetatarsal), revascularisation by catheter-based interven-
tions (PTA, percutaneous transluminal angioplasty with or
without stenting) or surgical arterial reconstruction (profunda-
plasty, supra- and infrainguinal bypass grafting) and, ﬁnally,
major amputation (amputation proximal to the ankle). Patients
without speciﬁc treatment included those merely given analgesia
for pain.
Independent of initial treatment, all patients routinely received
an anti-platelet medication (acetylsalicylacid 100 mg, in case of
aspirin intolerance clopidogrel 75 mg) and a statin (simvastatin
40 mg). Following peripheral bypass surgery, all patients were
anticoagulated with heparin for 48 h. No additional anti-platelet
medication or anticoagulation was given after revascularisation
procedures. If necessary, appropriate management of hypertension
and diabetes was initiated and patients were encouraged to stop
cigarette smoking.
Whenever technically feasible and clinically reasonable, one
type of revascularisation was attempted. Patients eligible for
revascularisation were stratiﬁed by TASC classiﬁcation1 for inter-
vention and suitability for bypass surgery. Reintervention included
any invasive treatment performed in a limb previously intervened
on. Conservative treatment was chosen as initial approach in
patients who were non-ambulatory, had a limited life expectancy
or failed to give consent to an invasive treatment. Primary ampu-
tation was considered necessary only if the weight-bearing area of
the foot was irreversibly necrotic, the patient was non-ambulatory
with ﬁxed joint contractures, or for those who had no prospect of
walking again for any other reason.
To assess their predictive value for patient’s survival rate, limb
salvage rate and amputation-free survival rate, the following demo-
graphic and clinical characteristics were analysed: age, sex, stage of
peripheral arterial disease (PAD) either with rest pain (14 days) or
tissue loss (non-healing ulceration or gangrene), the presence of
diabetes mellitus (deﬁned as ongoing treatment with oral hypo-
glycaemic agents or insulin), hypertension (systolic blood pressure
140 mmHg and/or diastolic blood pressure 90 mmHg or ongoing
treatment with antihypertensive agents), hyperlipidaemia (low-
density lipoprotein (LDL)-cholesterol >100 mg dl1 and/or ongoing
lipid-lowering treatment) and smoking (current or past 5 years).
Additional characteristics were a history of major cardiac disease
(prior myocardial infarction, MI; congestive heart failure, CHF, New
York Heart Association class III and IV) cerebrovascular disease (prior
stroke; transitory ischaemic attack, TIA), renal disease (chronic renal
failure with creatinine >2 mg dl1 or end-stage renal disease,
ESRD, hemodialysis dependency) and pulmonary disease (chronic
obstructive pulmonary disease, COPD, deﬁned as forced expiratory
volume in 1 s (FEV1) < 80% of maximal age and gender predictive
value6).
To estimate the risk of adverse outcome according to an estab-
lished speciﬁc risk scoring method, all patients retrospectively
were scored according to the modiﬁed PREVENT III (P III) critical
limb ischaemia risk score.7,8 Points (pts) were assigned to each
patient for the presence of dialysis (4 pts), tissue loss (3 pts), age 
75 years (2 pts) and coronary artery disease (1 pt). Total scores werecalculated and used to stratify each patient into low- (3 pts),
medium- (4e7 pts) and high risk (8 pts) categories.7
Life table analysis was used to estimate cumulative patient
survival rate, limb salvage rate and amputation-free survival rate.
Life tables were compared by the log-rank test, and the Cox
proportional hazards regression model was used to evaluate the
effect of baseline risk factors on survival rates using univariate and
multivariate analysis. The results are presented as hazard ratio (HR)
and 95% conﬁdence interval (CI). Contingency table analysis with
FishereFreemaneHalton exact test was used to evaluate nominal
independence of risk factors. A P-value <0.05 was considered
statistically signiﬁcant.
Results
The median age of the patients was 77 (IQR, 68e82) years, and
57 (55%) were males. Patient demographic data, mode of presen-
tation, risk factors for arteriosclerosis and co-morbidities are
summarised in Table 1. Median follow-up was 28.3 months (range,
1e42 months). The majority of patients (78%) had non-healing
ulceration or tissue necrosis as clinical signs of PAD. Seven
patients (7%) were lost to follow-up because they had moved or
because of incapacitating co-morbid diseases.
Initial treatment of 24 patients with rest pain (N ¼ 27 limbs) is
summarised in Fig. 1. Revascularisation was performed in 56% (15/
27), non-operative treatment in 41% (11/27) and primary amputa-
tionwas necessary in one patient. Initial revascularisation included
surgical arterial reconstruction in 73% (11/15) and endovascular
procedures with PTA and stent application in 27% (4/15). Following
the initial treatment, in total, six limbs (22%) required further
interventions for remaining CLI, including surgical reconstructions
and secondary amputations (Table 2).
Extent of trophic lesions and initial treatment of 80 patients
with tissue loss (N ¼ 88 limbs) are summarised in Fig. 2. Twenty
ischaemic wounds (23%) were infected at the time of admittance
and were treated accordingly. In total, 68% (60/88) received some
form of revascularisation: surgical arterial reconstruction in 50%
(30/60) and PTA in 50% (30/60), respectively. In 16% (14/88), limbs
Figure 1. Initial treatment of patients with rest pain (n ¼ 27 limbs).
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before a conservative therapy could be initiated. Primary major
amputation was necessary in nine patients and minor amputation
was performed twice as primary treatment. Further 16 minor
amputations were performed secondarily after previous
revascularisation.
The majority of readmissions for CLI occurred during the ﬁrst
year of the survey: 73 patients (70%) were admitted to the hospital
once, 24 patients (23%) twice, and seven patients (7%) required
more than two readmissions for CLI within the ﬁrst 12 months.
Thereafter, only six patients were readmitted for CLI: four patients
had recurrent CLI of their index limb and received angioplasty
(n ¼ 2), lumbar sympathicolysis (n ¼ 1) or major amputation
(n ¼ 1), respectively. One of these patients required additional
surgical revascularisation of the contralateral leg. Two patients
were readmitted for newly discovered CLI of the contralateral limb
andwere treated by surgical revascularisation, while their index leg
had sufﬁciently been revascularised initially.Table 2
Secondary procedures in patients with rest pain (n ¼ 27 limbs) and tissue loss
(n ¼ 88 limbs).
Procedure Rest pain Tissue loss
n n
Axillo-femoral BP 1
Aortofemoral BP 1
IBG 1 2
PTA inﬂow 1
PTA outﬂow 4
Sympathicolysis 1 1
Secondary amputation 2 3
Total 6 11
BP, bypass; IBG, infrainguinal bypass graft; PTA, percutaneous transluminal
angioplasty.In total, 17 limbs (15%) required reintervention of the limb
initially intervened on, including revascularisation by bypass graft,
angioplasty of the runoff vessels after arterial reconstruction and
secondary amputation due to irremediable graft occlusion (Table 2).
Onemajor amputationwas necessary after failed PTA. In 17 patients,
minor amputations were performed following revascularisation.
Patient survival rate was 65%, 55% and 41% at 1, 2 and 3 years.
Diabetes (HR, 1.85; 95% CI, 1.08e3.13; P ¼ 0.04), a history of major
cardiac disease (HR, 2.04; 95% CI, 1.19e3.51; P ¼ 0.02), and renal
insufﬁciency (HR, 3.20; 95% CI, 1.35e7.60; P < 0.01) were
predictive of poor survival (Table 3). For patients with renal
disease the risk for death increased with severity of renal insuf-
ﬁciency: creatinine 2 mg dl1 (HR, 2.1; 95% CI, 1.2e3.9;
P ¼ 0.008), creatinine > 2 mg dl1 (HR, 4.6; 95% CI, 1.9e11.0;
P ¼ 0.008) and ESRD (HR, 5.3; 95% CI, 2.2e12.7; P ¼ 0.008). On
multivariate analysis combined cardiac disease and renal insufﬁ-
ciency (HR, 4.96; 95% CI, 1.87e13.16; P < 0.01) predicted poor
patient survival (Table 4). Analysis for independence revealed that
cardiac disease and renal diseasewerenot independent risk factors:
the prevalence ofmajor cardiac disease increased signiﬁcantlywith
the severity of renal insufﬁciency (c2, 5.8; DF, 1; P ¼ 0.016).
At 1, 2 and 3 years, freedom from major amputation was 81%,
80% and 73%, respectively. None of the risk factors analysed affected
limb salvage rate.
Amputation-free survival rate at 1, 2 and 3 years was 56%, 46%
and 31%. By univariate analysis, the predictors of major amputation
and/or deathwere prior cardiac disease (HR,1.74; 95% CI,1.06e2.82;
P ¼ 0.03), and renal insufﬁciency (HR, 2.68; 95% CI, 1.23e5.86;
P < 0.001) (Table 3). On multivariate analysis, again only the
combination of cardiac and renal disease predicted poor
amputation-free survival (HR, 3.68; 95% CI, 1.52e8.95; P < 0.01)
(Fig. 3). Stratiﬁcation of the patients by P III risk categories yielded
three signiﬁcantly different estimates for 1- and 3-year amputation-
free survival with low risk 77.8% (36.3% of cohort), medium risk
Figure 2. Initial treatment of patients with tissue loss (n ¼ 88).
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31.8%, 0% (P < 0.001 for each comparison), respectively. For each
increase in risk category the HR was 1.98 (95% CI, 1.29e3.02;
P ¼ 0.002) for amputation and/or death.
After three years, functional outcome of 61 patients could be
assessed: walking distance was unlimited in 26 patients, at least
1000 m in six patients and less than 1000 m in 10 patients. In fourTable 3
Univariate analysis (HR, hazard ratio and 95% CI) for risk factors for survival and
amputation and/or death in patients with CLI (ischaemic lesions compared to rest
pain; all others coded yes/no).
Risk factors Patient survival Amputation-free survival
HR (95% CI) P-value HR (95% CI) P-value
Ischaemic lesion 1.03 (0.54e1.97) 0.84 0.94 (0.53e1.67) 0.87
Diabetes 1.85 (1.08e3.13) 0.04 1.52 (0.91e2.56) 0.11
Hypertension 0.77 (0.29e1.71) 0.60 1.30 (0.68e2.52) 0.38
Hyperlipidaemia 1.27 (0.66e2.45) 0.63 1.08 (0.59e1.98) 0.95
Smoker 1.59 (0.94e2.67) 0.05 0.98 (0.62e1.69) 0.87
Renal disease 3.20 (1.35e7.60) <0.01 2.68 (1.23e5.86) <0.001
Cardiac disease 2.04 (1.19e3.51) 0.02 1.74 (1.06e2.82) 0.03
Pulmonary disease 1.86 (1.01e3.45) 0.06 1.71 (0.85e3.44) 0.10
Cerebral ischaemic disease 1.85 (0.91e3.74) 0.06 1.48 (0.79e2.79) 0.17patients, ambulation was restricted to their home, one patient was
bedridden and 14 patients had major amputation. In total, 32 of
these patients had received one type of revascularisation (24
surgical reconstructions and eight interventions). Thirty-one of
these revascularised patients were able to move independently
with walking distances of at least 1000m, and one patient reported
having rest pain.Table 4
Multivariate analysis (HR, hazard ratio and 95% CI) for risk factors for survival in
patients with CLI (ischaemic lesions compared to rest pain; all others coded yes/no).
Risk factors Patient survival
HR (95% CI) P-value
Diabetes 1.49 (0.58e3.85) 0.40
Hypertension 0.38 (0.09e1.54) 0.17
Hyperlipidaemia 0.57 (0.17e1.91) 0.36
Smoker 1.19 (0.44e3.21) 0.05
Renal disease 7.47 (0.88e63.47) 0.07
Cardiac disease 2.18 (0.81e5.87) 0.12
Cardiac and renal disease 4.96 (1.87e13.16) <0.01
Pulmonary disease 3.41 (0.66e17.67) 0.14
Cerebral ischaemic disease 1.87 (0.55e6.27) 0.31
Figure 3. KaplaneMeier estimates for amputation-free survival according to different
groups of patients: 1 (-) without cardiac or renal disease; 2 (>) with cardiac or renal
disease; 3 (C) combined cardiac and renal disease. The standard error (SE) remains
<10% throughout.
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This study demonstrates that two-thirds of all patients pre-
senting with their ﬁrst episode of CLI to a vascular surgical centre
can be offered some form of direct revascularisation. Approxi-
mately half of these candidates for revascularisation will undergo
surgery and half can be treated by catheter-based interventions.
Patients not eligible for revascularisatione approximately one-ﬁfth
of all patients e can be offered at least some type of medical and
general supportive treatment. Primary amputation is required in
less than 10%, and for only few patients (<5%) there are no treat-
ment options available.
Based on a previous report from the Vascular Surgical Society
of Great Britain and Ireland9 Huntington et al. published revised
guidelines for the management of CLI, set from the ﬁgures of
a multi centre study on investigation and treatment of patients
with lower limb occlusive arterial disease in the North of
England.10 According to these guidelines, a revascularisationTable 5
Summary of selected reports of initial treatment and outcome of patients with critical li
Author year Taylor
199111
Hickey
199112
Tyrrell
199315
Sayers
199413
Vascular Surgical
Society 19959
I.C.A.I.-G
199633/
Study design Single
Centre
Single
Centre
Multi
Centre
Single
Centre
Multi Centre Multi C
No. of Patients/Limbs 498/
627
369 213 209/
232
679 574
Diabetic 43% 24% 16% 36% 30% 30%
Rest Pain 46%a e e 47% 74% 88%
Tissue Loss 54%a e e 53% 66% 64%
1 y Survival Rate 82%a e 79% 75% e 22%1997
mortali
1 y Limb Salvage Rate 95%a e 72% 74% e e
Revascularisation 98% 85%b 68% 89% 63% 49%c
Surgery 100% 100% 96% 53% 74% 42%
Endovascular e e 2% 23% 34%e 7%
Surgery þ Endovascular e e 2% 1% 6% e
Primary Amputation 2% 12%b 13% 8% 16% 9%c
Conservative e e 19% 3% 8% 42%g
No Treatment e 2%b e e 13% e
a Only revascularised limbs.
b Calculated from data in published text.
c At time of recruitment.
d Referrals.
e Including lysis.
f Procedures performed.
g Including sympathectomy, epidural spinal electrostimulation, minor amputation.
h Including patients with previous vascular interventions.should be attempted in 70% e by radiology in 45% and by surgery
in 58% e and primary amputation should be limited to 8% (95% CI,
6e10%). These recommendations favour very well with the data
in the present study obtained from a major German vascular
surgical centre (Table 5). In some specialised vascular units with
a more aggressive approach towards revascularisation, more than
80% of the patients with CLI had an attempt.8,1114 However, these
were all single centre experiences, whereas revascularisation
rates from multi centre studies, possibly representing average
patient care more accurately, usually are lower in a range of
60e70%.9,10,15,16
During the last 15 years, percutaneous transluminal angioplasty
(PTA) has rapidly developed to a ﬁrst-line treatment for CLI.17,18
Although only few reports on initial treatment of CLI give
detailed information on the proportion of PTA and hybrid surgical
procedures,1416,19 the data in Table 5 demonstrate the growing
importance of endovascular procedures for primary management
of CLI over the years. With 45% PTA utilisation for initial revascu-
larisation, the data of the present study compared favourably with
recent studies where the percentage of primary PTA was between
36%16 and 45%.10
Meanwhile specialised centres attempt revascularisation by
PTA in more than 50%, with outcomes similar to bypass
surgery.5,17,20 On the other hand, primary bypass surgery is rec-
ommended for patients with life expectancy of more than 2 years
because of the improved durability of the reconstruction.5 Never-
theless, continuing improvements in endovascular technology will
further increase the role of endovascular procedures as ﬁrst-line
treatment for CLI, especially in patients deemed at high risk for
surgery.
Although infrainguinal bypass grafting for limb-threatening
ischaemia can achieve acceptable graft patency rates even in
dialysis-dependent patients,21 there is ample evidence that ESRD is
associated with early secondary amputation,4,11 and extremely
poor patient survival.21,22 Consistently, in the present study severe
renal insufﬁciency proved to be a powerful predictor of poor
survival (HR, 5.3) and amputation-free survival (HR, 2.7). Further-
more, patients with moderate, not end-stage, renal insufﬁciencymb ischaemia.
roup
199727
Varty
199618
Holdsworth
199719
Holdsworth
199714
Huntington
200010
Bailey
200326
Awad
200616
Present
Study
entre Single
Centre
Single
Centre
Single
Centre
Multi
Centre
Single
Centre
Single
Centre
Single
Centre
188/
198
319/436d 228/275 1120 only
CLI
130/
149f
113/
113
104/
115
36% 26% 23% e 30% 39% 55%
35% e 61% e 22% 79% 22%
65% e 39% e 78% 78% 78%
ty
e 70% 69% e e 92% 65%
79% 57% 83% e 61% 85% 81%
73% 43% 86%h 70% 42% 70% 65%
24% 84% 83% 58% 23% 34% 55%
42% 16% 17% 45% 19% 30% 45%
6% e e 6% e 6% e
10% 18% 7% 8% 7% 14% 9%
17%h 20% 8%g e 47% 16% 22%g
e 19% e e e 4%
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Owens et al. observed a nearly linear relationship between dete-
riorating renal function and abbreviated survival in patients
undergoing lower extremity bypass surgery, beginning well before
the onset of dialysis.23 In combination with major cardiac disease,
any degree of renal insufﬁciency adversely affected limb salvage
and patient survival with a ﬁvefold risk of death within 3 years.
Hereby, renal insufﬁciency seems to be the predominant risk factor,
as the presence of cardiac disease signiﬁcantly increased with
severity of renal failure.
The PREVENT III risk score is a well-validated tool to predict
amputation-free survival in patients with CLI considered for
infrainguinal bypass surgery7 or endovascular procedures.8 In
the present study, all patients were included, resulting in
a slight shift towards medium risk (57% of cohort vs. 43%7) and
high risk (7% of cohort vs. 6%7 and 4%8, respectively). Well in
accordance with previous studies7,8 estimated amputation-free
survival rates associated with each risk category deteriorated
with increasing risk (HR 1.98 for each risk category). Stratiﬁca-
tion to the high risk group was associated with particularly poor
outcome with all patients amputated or dead after 3 years.
However, 1- and 3-year amputation-free survival rates were
inferior in all three risk categories compared to previous
reports.7,8 The reason for this poor outcome remains unclear.
Possibly the inclusion of all patients presenting with CLI
contributed to this comparatively poor outcome. These unse-
lected data might, however, represent the situation in non-
specialised centres more accurately.
Diabetes is frequently associated with renal failure, cardiovas-
cular disease and neuropathy. Furthermore, progression of CLI is
accelerated in diabetics, increasing the incidence of gangrene.14
Therefore, this problematic group is at particular risk when pre-
senting with their ﬁrst episode of CLI. In accordance with others, in
the present study diabetes was an independent risk factor for poor
survival,24,25 not, however, for limb salvage11,13,25 and amputation-
free survival. These ﬁndings are not consistent in literature, as some
authors report no inﬂuence of diabetes on survival,13,15,18,26,27 and
others adverse effects on limb salvage.15,18,24,26,27 As diabetes seems
to add an unpredictable element to clinical outcome, it has been
pointed out that diabetics risk to undergo infrainguinal bypass
surgery less often or more selective than non-diabetic patients.9,28
In the present series, diabetes did not have any impact
on revascularisation practice. Despite the high proportion
of diabetics, revascularisation was attempted in 65%, with
no differences between diabetics and non-diabetics. This aggressive
approach towards revascularisation of diabetic patients was
encouraged by own experience2931 and recent reports on high
success rates of arterial reconstructions in these patients.4,16,32
Furthermore, an attempt seems justiﬁed if technically feasible, as
diabetics very well beneﬁt from bypass surgery in terms of quality
of life, albeit to a lesser extent than non-diabetic patients.30,31
In only few patients ﬁnal functional outcome could be assessed,
as survival of patients with CLI generally is poor, especially in
cohorts with a high incidence of diabetes and renal insufﬁciency, as
in this series. Half of the surviving patients had received some form
of revascularisation, and nearly all revascularised patients with
viable limbs were able to walk at least 1 km independently without
any help. Although patients allocated to the different treatment
options are by no means comparable, these results seem to advo-
cate early revascularisation whenever technically feasible and
clinically reasonable.
In conclusion, two-thirds of all patients presenting with their
ﬁrst episode of CLI can be offered some form of direct revascular-
isation. The growing role of endovascular procedures as ﬁrst-line
treatment will possibly increase the number of patients eligiblefor revascularisation, especially in patients deemed at high risk for
surgery.
After successful revascularisation, functional outcome is
encouraging. However, life expectancy remains poor in patients
with CLI, especially in the presence of renal insufﬁciency and major
cardiac disease. This knowledge may be of use to clinicians in
assessing and communicating risk and prognosis of patients pre-
senting with CLI.
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